Magda Marquet - Jun 14, 2024 Form 4 Insider Report for Arcturus Therapeutics Holdings Inc. (ARCT)

Role
Director
Signature
/s/ Ilan Katz, attorney-in-fact
Stock symbol
ARCT
Transactions as of
Jun 14, 2024
Transactions value $
$0
Form type
4
Date filed
6/18/2024, 09:00 PM
Previous filing
Jun 21, 2024
Next filing
Jun 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARCT Common Stock Options Exercise $0 +3.13K $0.00 3.13K Jun 14, 2024 Direct F1
holding ARCT Common Stock 24.9K Jun 14, 2024 Via Alma Life Sciences, LLC

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARCT Deferred Stock Units Options Exercise $0 -3.13K -100% $0.00* 0 Jun 14, 2024 Common Stock 3.13K $0.00 Direct F1, F2
transaction ARCT Stock option (right to buy) Award $0 +15K $0.00 15K Jun 14, 2024 Common Stock 15K $31.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.
F2 Represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.
F3 Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.